CAS: 1711-09-7; 3-Bromobenzoylchloride

该化合物是一种有机溴化合物,通常用作有机合成的多功能中间体,其反应性乙基氯组能够产生有效的相互碰撞反应,使其对生产药品,农用化学品和特殊化学品具有价值.在元体位置上的溴替代为通过交叉或核生殖替代进一步功能化提供了独特的反应性.这种复合体在储存于无水条件下时具有很高的纯度和稳定性.它在建造复杂的芳香框架,特别是在药用化学中具有效用,凸显了其作为建筑构件的重要性.适当的处理由于其湿度敏感度和腐蚀性而必不可少.

结构式图片

相似化合物

3132-99-8 56990-02-4 188813-04-9

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号591-18-4 1-溴-3-碘苯 | CAS号201230-82-2 carbon monoxide | CAS号585-76-2 3-溴苯甲酸 | CAS号98-88-4 苯甲酰氯 | CAS号3132-99-8 间溴苯甲醛 | CAS号39115-96-3 3-溴苄肼 | CAS号35306-74-2 3-溴-N-丙基苯甲酰胺 | CAS号49834-22-2 3-溴-N-甲基苯甲酰胺 | CAS号4885-18-1 (3-溴苯基)二甲胺 | CAS号93002-99-4 6-(3-Bromopheny... | CAS号1829-88-5 (3-bromobenzoyl... | CAS号188747-28-6 3-bromo-N-(6-me... | CAS号3469-20-3 2,3-二苯基吲哚 | CAS号24167-51-9 3-溴-N,N-二甲基苯甲酰胺

合成工艺路线路线简述

  • 合成目标产物 3-Bromobenzoyl Chloride 主要起始原料 3-Bromobenzoic Acid
  • (文献来源)合成步骤主要原料 3-Bromobenzoic Acid
间溴苯甲酸置于草酰氯,N,N-二甲基甲酰胺体系中,用 二氯甲烷 用作溶剂,化学反应生成3-溴苯甲酰氯
参考文献:芳基环丙胺-伏立诺他偶联物的癌细胞选择性靶向
标题:芳基环丙胺-伏立诺他偶联物的癌细胞选择性靶向
摘要:与传统的大分子药物递送系统相比,小分子抗癌药物递送具有许多优点.我们之前开发了苯基环丙胺 (Pcpa)-药物缀合物 (Pdc) 作为基于小分子的药物递送载体,用于靶向赖氨酸特异性脱甲基酶 1 (Lsd1) 过表达的癌症.在本研究中,我们将这种 Pdc 策略应用于 Hdac 抑制性抗癌药物伏立诺他 (Vorinostat).在三种合成的 Pcpa 或芳基环丙胺 (Acpa)-伏立诺他缀合物1,9和32中,具有 4-氧苄基连接体的缀合物32在缓冲溶液中表现出足够的稳定性,有效的 Lsd1 抑制,有效的 Lsd1 依赖性伏立诺他释放以及有效和选择性的抗增殖作用对表达 Lsd1 的人乳腺癌和小细胞肺癌细胞系的活性.这些结果表明缀合物在癌细胞中选择性地释放伏立诺他.类似的策略可能适用于其他抗癌药物.
Doi:10.1021/acsmedchemlett.2C00126

海关参考信息

专利信息


专利号:US-11130764-B2
优先权日:2017-02-17
标题 :Analogs of vincamine and uses thereof
发明人:HUIGENS III ROBERT WILLIAM; NORWOOD IV VERRILL M; LUESCH HENDRIK
权利人:UNIV FLORIDA
摘要:The present disclosure provides compounds of any one of Formulae (I′), (I), (IA), (II′), (II), (IIA), (IIIA), (III″), (III′), (III), (IIIA), (IV), (V′), (V), (VI), (VII), (VIII′), (VIII), (IX′), (IX), and (X). The compounds described herein may be useful in treating and/or preventing a broad range of diseases (e.g., proliferative disease (e.g., cancers (e.g., non-small cell lung cancer, or glioma), inflammatory diseases, autoimmune diseases), CNS disorder (e.g., drug addiction), metabolic disorder (e.g., diabetes), or infectious disease (e.g., bacterial infection or parasitic infection (e.g., malaria))). Also provided in the present disclosure are pharmaceutical compositions, methods of synthesis of a compound described herein, kits, methods, and uses including or using a compound described herein.

专利号:RU-2014320-C1
优先权日:1987-09-15
标题:Method of synthesis of propenoic acid derivatives and their stereoisomers

专利号:CN-103864722-A
优先权日:2012-12-13
标题 :Synthesis of a Novel [4-(4-Phenoxymethyl)benzoyl]piperazine Derivatives and Their Anticancer Drug Actions

专利号:US-2012009151-A1
优先权日:2007-12-21
标题 :Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof
发明人:HAN AMY QI; COBURN GLEN A; PROVONCHA KATHLEEN P; ROTSHTEYN YAKOV
权利人:HAN AMY QI; COBURN GLEN A; PROVONCHA KATHLEEN P; ROTSHTEYN YAKOV; PROGENICS PHARM INC
摘要:Disclosed herein are novel triazines and related compounds, the synthesis thereof, and compositions, including pharmaceutical compositions, comprising the novel triazines and related compounds. Such novel triazines and related compounds function to inhibit or block entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.

专利号:WO-2009054923-A2
优先权日:2007-10-24
标 题 :Synthesis and crystalline forms of cb-1 antagonist/inverse agonist

专利号:US-2010292282-A1
优先权日:2007-10-24
标题:Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
发明人:CAMPOS KEVIN R; CHEN CHENG-YI; FOLEY JENNIFER R; HILLIER MICHAEL; JEN WENDY S; KASSIM AMUDE M; KLAPARS ARTIS; PERESYPKIN ANDREY V; ROSNER THORSTEN; SAVARIN CECILE G; TUDGE MATTHEW; VARIANKAVAL NARAYAN; VYDRA VICKY; ZHAO DALIAN
权利人:CAMPOS KEVIN R; CHEN CHENG-YI; FOLEY JENNIFER R; HILLIER MICHAEL; JEN WENDY S; KASSIM AMUDE M; KLAPARS ARTIS; PERESYPKIN ANDREY V; ROSNER THORSTEN; SAVARIN CECILE G; TUDGE MATTHEW; VARIANKAVAL NARAYAN; VYDRA VICKY; ZHAO DALIAN
摘要:The present invention relates to a process for producing crystalline 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methyl-propyl]-5-fluorobenzonitrile, and novel salts, solvates, hydrates and polymorphs thereof.
浙江扬帆新材料股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.shoufu.cn
企业联系电话:0571-88902507;0571-88902517;0571-88902509👤
📞浙江扬帆新材料股份有限公司 ⚠️参考联系方式
联系人:唐小姐
电话:0571-88902507;0571-88902517;0571-88902509

传真:0571-88902500
邮箱:shoufu@shoufuchem.com
通信地址: 浙江省杭州市滨江区信诚路31号扬帆创业大厦
邮编: 310051
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:浙江省杭州市滨江区信诚路31号扬帆创业大厦
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


摘要:Ley, S. V.; Browne, D. L.; OʼBrien, M., Science of Synthesis: Flow Chemistry in Organic Synthesis, (2018) 1, 277.
摘要:Li, X.; Song, Q., Science of Synthesis: Knowledge Updates, (2024) 1, 324.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知